Component

Reported psychosis after starting ALCAR

Reported psychosis after starting ALCAR

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Psychosis occurred five days after ALCAR was started in a published bipolar-disorder case report.

    Experimental context and source evidence
    evidence_access
    Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    experimental_model
    52-year-old man; ALCAR 500 mg/day alongside newly added vitamins C/E, ongoing lithium and citalopram; prior recurrent illness.
    interpretation_status
    Source-derived curation with stated access limits; ungraded, not independent replication.
    limitations
    Single confounded case; this is a signal, not a quantified risk or proof that ALCAR invariably triggers psychosis.
    nutrient_topic
    Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation. · Acetyl-L-carnitine
    plain_language
    Psychosis occurred five days after ALCAR was started in a published bipolar-disorder case report.
    primary_references
    Psychosis Precipitated by Acetyl-l-Carnitine in a Patient With Bipolar Disorder. | https://pubmed.ncbi.nlm.nih.gov/17599177/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC1894836/ | https://doi.org/10.4088/pcc.v09n0114d
    source_locator
    Reviewed reference psychosis-case; Temporal association and author attribution are recorded. No rechallenge, incidence estimate or proven dopamine-mediated cause is established.

    Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026) · lines 611–617

    AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed. · supports · 52-year-old man; ALCAR 500 mg/day alongside newly added vitamins C/E, ongoing lithium and citalopram; prior recurrent illness. · Recorded from source · Recorded from source

    ### psychosis-case Psychosis occurred five days after ALCAR was started in a published bipolar-disorder case report. Temporal association and author attribution are recorded. No rechallenge, incidence estimate or proven dopamine-mediated cause is established. Model and exposure: 52-year-old man; ALCAR 500 mg/day alongside newly added vitamins C/E, ongoing lithium and citalopram; prior recurrent illness. Limitations: Single confounded case; this is a signal, not a quantified risk or proof that ALCAR invariably triggers psychosis. Reference: Psychosis Precipitated by Acetyl-l-Carnitine in a Patient With Bipolar Disorder. | 2007 | https://pubmed.ncbi.nlm.nih.gov/17599177/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC1894836/ | https://doi.org/10.4088/pcc.v09n0114d | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.